Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Anoma NelloreDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0002-2489-2838
Julie HoupDivision of Transplant Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
John T KillianDivision of Transplant Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Ajit P LimayeDivision of Infectious Diseases, University of California at San Francisco, San Francisco, CA 94143, USA.
Cynthia E FisherDivision of Infectious Diseases, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0001-6661-9162
Funding
Tissue and organ specific human B cell immunity: Supplement - Metabolic Risk Factors and Inflammation in PASC DevelopmentU19AI142737 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RANDALL, TROY D · 2019 to 2023
$19.7M
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)U01AI163090 · NIAID · UNIVERSITY OF WASHINGTON · PI Don J Diamond, Cynthia E Fisher · 2021 to 2026
$17.4M
Advancing Transplantation Outcomes in ChildrenU01AI163072 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI David M. Briscoe · 2021 to 2026
$15.3M
Project 3: Evolution, dynamics and durability of B cell and antibody responses in lung transplantationU19AI181105 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Troy D Randall · 2024 to 2026
$13.9M
A Randomzied Phase II Trial of CMV Prevention in Acute Lung InjuryU01HL102547 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J, LIMAYE, ABHIJIT PRAKASH · 2010 to 2014
$5.9M
Kidney transplant Preemptive therapy or Prophylaxis (KPoP) for CMVPreventionin D+R- RecipientsR01AI184205 · NIAID · UNIVERSITY OF WASHINGTON · PI Daniel Conlon Brennan, Cynthia E Fisher · 2024 to 2026
$5.1M
Respiratory Viral Determinants of Chronic Lung Allograft DysfunctionK23HL143050 · NHLBI · UNIVERSITY OF WASHINGTON · PI FISHER, CYNTHIA E · 2018 to 2022
$986k
Assessing Flu-specific Humoral Immunity in Human Lung after Ex Vivo Lung PerfusionR21AI152006 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NELLORE, ANOMA, RANDALL, TROY D · 2020 to 2021
Chronic lung allograft dysfunction (CLAD) is the most common cause of long-term lung allograft failure. Several factors, including respiratory virus infection (RVI), have been associated with CLAD development, but the underlying mechanisms of these associations are not well understood. We hypothesize that RVI in lung transplant recipients elicits the development of donor-specific antibodies (DSAs), thus providing a mechanistic link between RVI and CLAD development. To test this hypothesis, we retrospectively evaluated for the presence of HLA antibodies in a cohort of lung transplant recipients with symptomatic RVI within the first four months post-transplant using sera at two time points (at/directly after the transplant and following RVI) and time-matched controls without RVI (post-transplant). We found a trend toward the development of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Association between Respiratory Virus Infection and Development of · full record | Socratic